Skip to main content

Table 4 Univariate prognostic analysis of overall survival and disease-free survival in TNM stage I HCC patients

From: Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma

Variables

Overall survival rate (%)

Disease-free survival rate (%)

 

3 y

5 y

P value

3 y

5 y

P value

Gender

      

   Female (n = 9)

100.0

81.8

0.438

77.8

77.8

0.473

   Male (n = 58)

75.7

71.1

 

62.3

62.3

 

Age (years)

      

   ≤ 50 (n = 32)

87.4

80.4

0.213

71.3

71.3

0.560

   > 50 (n = 35)

73.0

65.7

 

59.4

59.4

 

HBsAg status

      

   Negative (n = 13)

83.9

83.9

0.752

76.2

76.2

0.426

   Positive (n = 54

78.2

69.4

 

62.1

62.1

 

AFP (μg/l)

      

   ≤ 400 (n = 43)

71.0

65.3

0.199

62.1

62.1

0.690

   > 400 (n = 24)

91.1

82.8

 

68.0

68.0

 

Cirrhosis

      

   No (n = 8)

100.0

100.0

0.128

75.0

75.0

0.565

   Yes (n = 59)

76.0

67.5

 

63.2

63.2

 

Child-Pugh classification

     

   A (n = 61)

78.9

75.5

0.499

67.2

67.2

0.519

   B (n = 6)

83.3

55.6

 

44.4

44.4

 

Tumour size (cm)

      

   ≤ 5 (n = 40)

82.6

82.6

0.061

77.7

77.7

0.006

   > 5 (n = 27)

73.0

57.0

 

45.7

45.7

 

Tumour capsule

      

   Complete (n = 26)

81.0

81.0

0.787

67.3

67.3

0.957

   No/incomplete (n = 41)

79.1

68.3

 

63.3

63.3

 

Edmondson-Steiner grade

     

   I/II (n = 46)

80.9

80.9

0.172

68.3

68.3

0.338

   III/IV (n = 21)

73.7

60.0

 

57.1

57.1

 

MACC1 expression level

     

   Low (n = 37)

85.6

85.6

0.021

76.5

76.5

0.017

   High (n = 30)

71.1

53.3

 

49.4

49.4

 
  1. MACC1, metastasis-associated in colon cancer-1; HCC, hepatocellular carcinoma; AFP, α-fetoprotein; HBsAg, hepatitis B surface antigen.